Treatment of Unacceptable Bleeding Patterns in ETG Implant Users With an Oral Contraceptive

NCT01963403 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

26

Enrollment

OTHER

Sponsor class

Stopped Futility of recruitment

Conditions

Abnormal Uterine Bleeding, Unspecified
Uterine Bleeding Heavy

Interventions

DRUG: EE 30mcg/LNG 150mcg
DRUG: Placebo

Sponsor

University of California, Davis

Collaborators

[object Object]